SR One is a transatlantic biotechnology venture capital firm that partners with founders and entrepreneurs to translate innovative science into transformative medicines. Originally founded in 1985 as the corporate venture capital arm of GlaxoSmithKline, SR One completed its spin-out from GSK in 2020 and now operates as an independent firm with offices in Redwood City, California, and London. Its most recent fund (Fund II) closed at $600 million in March 2023.
60% of their portfolio is in Biotech & Life Sciences. Deal activity increased 33% year-over-year (8 deals in the last 12 months). Average disclosed round size is $90.7M (across 67 rounds with reported amounts).
Portfolio
61
Fund Size
$600M
Top Stage
Series B
Last 12 Mo
7
Team
Lyla Youssef, PhD
Associate
Amit Mehta, PhD
US Investments
Briana Wilson
Senior Administrative Assistant
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| CCrystalys Therapeutics | Series B | $130M | Jul 2026 |
 FORE Biotherapeutics | Unknown | $67.4M | Jul 2026 |
 Immutrin | Series A | $87M | Mar 2026 |
 Corxel | Series D | $287M | Jan 2026 |
 Addition Therapeutics | Unknown | $100M | Dec 2025 |
 Veradermics | Series C | $150M | Oct 2025 |
 Mission Therapeutics | Unknown | $13.3M | Oct 2025 |
 CHARM Therapeutics | Series B | — | Sep 2025 |
| FORE Biotherapeutics | Series D | $38M | May 2025 |
| FFore Bio | Series D | $38M | May 2025 |
 Windward Bio | Series A | $200M | Jan 2025 |
 Draig Therapeutics | Series A | $140M | Jan 2025 |
 Avenzo Therapeutics | Series B | $60M | Jan 2025 |
 Antag Therapeutics | Series A | — | Dec 2024 |
| Avenzo Therapeutics | Unknown | $386M | Nov 2024 |
 Elektrofi, Inc. | Series C | $112.3M | Oct 2024 |
| EElektrofi | Series C | $112.3M | Oct 2024 |
 Asceneuron | Series C | $100M | Jul 2024 |
 Alumis | Series C | $259M | Mar 2024 |
| Asceneuron | Series C | $100M | Jan 2024 |
 Nomic Bio | Series B | $42M | Jan 2024 |
 Avalyn Pharma | Series C | $175M | Sep 2023 |
| AAdaRx Pharmaceuticals | Series C | $200M | Aug 2023 |
| AAdarx | Series C | $46M | Jan 2023 |
 Rezo Therapeutics | Series A | $78M | Nov 2022 |
Top Co-Investors
Last updated: 7 September 2026